CollPlant Biotechnologies entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the company’s ordinary shares (or ordinary share equivalents in lieu thereof).
Gross proceeds from the private placement are expected to be approximately $2.6 million. CollPlant intends to use the net proceeds for general corporate purposes, including working capital, R&D programs, and continued evaluation of strategic business combinations, including potential acquisitions, joint ventures, and other strategic transactions.
The company’s Vergenix STR is based on the company’s rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons.
CollPlant Biotechnologies entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the company's ordinary shares (or ordinary share equivalents in lieu thereof).
Gross proceeds from the private placement are expected to be approximately $2.6 million. CollPlant intends to use the net proceeds for general...
CollPlant Biotechnologies entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the company’s ordinary shares (or ordinary share equivalents in lieu thereof).
Gross proceeds from the private placement are expected to be approximately $2.6 million. CollPlant intends to use the net proceeds for general corporate purposes, including working capital, R&D programs, and continued evaluation of strategic business combinations, including potential acquisitions, joint ventures, and other strategic transactions.
The company’s Vergenix STR is based on the company’s rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons.
Copy to clipboard 
